Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 90,4 M
EBIT 2017 13,0 M
Net income 2017 -0,14 M
Debt 2017 72,1 M
Yield 2017 -
Sales 2018 130 M
EBIT 2018 28,2 M
Net income 2018 13,0 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 40,33
EV / Sales2017 5,90x
EV / Sales2018 4,09x
Capitalization 461 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
10:12p TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Submission of Matters to a Vote of S..
10:11p TELIGENT, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
05/16 TELIGENT, INC. : To Present At Bank Of America Merrill Lynch Healthcare Conferen..
05/10 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Results of Operations and Financial ..
05/10 TELIGENT : Results of Operations and Financial Condition, Financial Statements a..
05/10 TELIGENT : Management's Discussion and Analysis of Financial Condition and Resul..
05/03 TELIGENT, INC. : To Present At Deutsche Bank 42nd Annual Health Care Conference ..
05/03 TELIGENT : tops 1Q profit forecasts
05/02 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
05/02 TELIGENT, INC. : Announces First Quarter 2017 Results
More news
Sector news : Pharmaceuticals - NEC
07:35p JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
06:10p FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
Advertisement
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI89.51%463
JOHNSON & JOHNSON10.46%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.05%191 279
MERCK & CO., INC.9.65%175 160
More Results